Have your own idea? Try our Stock Screener
The Clinical Research and Equipment industry is up 16% in the last week, with WuXi Biologics (Cayman) up 8.7%. In the same time, Frontage Holdings was down 5.9%. This takes the industry's 12 month performance to a gain of 26%. Looking forward, earnings are forecast to grow by 42% annually.
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Tue, 11 Feb 2025 | HK$180.9b | HK$35.7b | -HK$1,061,504,029.70 | 57.5x | -170.5x | 5.1x |
Thu, 09 Jan 2025 | HK$147.8b | HK$35.6b | -HK$1,060,958,629.16 | 56.2x | -139.3x | 4.2x |
Sat, 07 Dec 2024 | HK$154.8b | HK$35.9b | -HK$1,058,516,453.32 | 54.1x | -146.2x | 4.3x |
Mon, 04 Nov 2024 | HK$153.9b | HK$35.7b | -HK$660,755,913.74 | 38x | -232.9x | 4.3x |
Wed, 02 Oct 2024 | HK$175.6b | HK$36.1b | -HK$650,693,031.77 | 35.4x | -269.9x | 4.9x |
Fri, 30 Aug 2024 | HK$125.6b | HK$36.1b | -HK$786,730,453.72 | 25.9x | -159.6x | 3.5x |
Sun, 28 Jul 2024 | HK$90.7b | HK$33.5b | HK$3.1b | 16.8x | 29.4x | 2.7x |
Tue, 25 Jun 2024 | HK$92.2b | HK$33.4b | HK$3.1b | 20.6x | 30x | 2.8x |
Thu, 23 May 2024 | HK$102.3b | HK$33.5b | HK$3.1b | 30.5x | 33.1x | 3.1x |
Sat, 20 Apr 2024 | HK$104.7b | HK$33.6b | HK$3.1b | 32.5x | 33.8x | 3.1x |
Mon, 18 Mar 2024 | HK$120.3b | HK$33.3b | HK$3.7b | 47.6x | 32.7x | 3.6x |
Wed, 14 Feb 2024 | HK$124.0b | HK$32.3b | HK$3.0b | 46.7x | 41.7x | 3.8x |
Fri, 12 Jan 2024 | HK$198.5b | HK$32.4b | HK$3.0b | 91.8x | 66.3x | 6.1x |
Sun, 10 Dec 2023 | HK$208.4b | HK$32.3b | HK$3.0b | 81.4x | 69.7x | 6.4x |
Tue, 07 Nov 2023 | HK$272.9b | HK$30.2b | HK$2.7b | 47.7x | 101.4x | 9x |
Thu, 05 Oct 2023 | HK$245.6b | HK$30.2b | HK$2.7b | 41.7x | 91.8x | 8.1x |
Sat, 02 Sep 2023 | HK$235.0b | HK$30.3b | HK$2.7b | 41.8x | 86.9x | 7.7x |
Mon, 31 Jul 2023 | HK$236.8b | HK$28.5b | HK$2.7b | 23.8x | 86.2x | 8.3x |
Wed, 28 Jun 2023 | HK$209.3b | HK$28.4b | HK$2.7b | 21.2x | 77x | 7.4x |
Fri, 26 May 2023 | HK$235.8b | HK$28.9b | HK$2.8b | 21.9x | 83.6x | 8.1x |
Sun, 23 Apr 2023 | HK$265.7b | HK$29.5b | HK$2.9b | 25.1x | 90.5x | 9x |
Tue, 21 Mar 2023 | HK$238.6b | HK$26.4b | HK$2.1b | 22.9x | 115.6x | 9x |
Thu, 16 Feb 2023 | HK$313.3b | HK$26.5b | HK$2.1b | 25.1x | 149.5x | 11.8x |
Sat, 14 Jan 2023 | HK$378.5b | HK$26.7b | HK$2.2b | 27.6x | 174.2x | 14.2x |
Mon, 12 Dec 2022 | HK$288.2b | HK$26.0b | HK$2.0b | 27.9x | 144.4x | 11.1x |
Wed, 09 Nov 2022 | HK$255.7b | HK$25.6b | HK$1.9b | 24.8x | 137.4x | 10x |
Fri, 07 Oct 2022 | HK$256.4b | HK$25.7b | HK$1.9b | 20.5x | 134.5x | 10x |
Sun, 04 Sep 2022 | HK$343.4b | HK$26.3b | HK$2.1b | 27.3x | 167.1x | 13x |
Tue, 02 Aug 2022 | HK$384.6b | HK$22.3b | HK$2.1b | 12x | 187.6x | 17.2x |
Thu, 30 Jun 2022 | HK$379.0b | HK$22.4b | HK$2.1b | 15.6x | 182.6x | 16.9x |
Sat, 28 May 2022 | HK$284.4b | HK$22.3b | HK$2.1b | 13.1x | 138.4x | 12.7x |
Mon, 25 Apr 2022 | HK$296.8b | HK$22.9b | HK$2.2b | 14.3x | 133.1x | 12.9x |
Wed, 23 Mar 2022 | HK$314.7b | HK$19.2b | HK$1.5b | 21.1x | 205.9x | 16.4x |
Fri, 18 Feb 2022 | HK$350.8b | HK$18.7b | HK$2.8b | 24.4x | 124.3x | 18.7x |
124.3x
How does Hong Kong Clinical Research and Equipment compare with similar industries?
HK Market | 4.44% | |
Healthcare | 7.16% | |
Life Sciences | 15.84% | |
Clinical Research and Equipment | 15.84% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
2269 WuXi Biologics (Cayman) | HK$21.40 | 8.7% +HK$7.0b | 23.6% | PE31.2x | |
2228 XtalPi Holdings | HK$6.70 | 24.5% +HK$4.5b | n/a | PS108.6x | |
2576 Zhejiang Taimei Medical Technology | HK$5.05 | 58.8% +HK$1.1b | n/a | PS4.6x | |
2268 WuXi XDC Cayman | HK$29.20 | 2.6% +HK$898.7m | 99.5% | PE55.2x | |
1873 Viva Biotech Holdings | HK$0.94 | 19.0% +HK$316.8m | 51.6% | PS0.9x |